Studiesinvestigating AML patient relapses after FLT3 inhibitor therapy have consistentlyidentified alterations in genes within the RAS/MAPK pathway, particularly NRAS andKRAS, as the most prevalent genetic aberrations associated with acquired resistance,alongside novel FLT3 mutations (9–11). This evidence concerns the gene FLT3 and acute myeloid leukemia.